Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.

Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that it will unveil the results of its U.S ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE ...

LAS VEGAS, Nov. 2, 2025 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results ...

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, ...